secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274634
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences adopts Severance and Change in Control Plan for top executives
--------------------------------------------------------------------------------

- Plan adopted Nov 3, 2023; covers CEO Maetzold, CFO Stokes, CCO Juvenal, COO Oelschlager.
- On CIC termination: CEO gets 36 months salary + 300% target bonus; others get 12 months salary + prior year bonus.
- On non-CIC termination: CEO gets 18 months salary + 150% target bonus; others get 12 months salary + 100% target bonus.
- Equity acceleration: 100% on CIC termination; pro-rata for 12/18 months on non-CIC termination.
- Plan replaces prior severance benefits under employment agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000119312523274634/0001193125-23-274634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000119312523274634/d530518d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer